MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
32.39
-1.14
-3.40%
After Hours: 32.32 -0.07 -0.22% 20:05 09/22 EDT
OPEN
33.80
PREV CLOSE
33.53
HIGH
34.04
LOW
32.37
VOLUME
823.74K
TURNOVER
0
52 WEEK HIGH
64.24
52 WEEK LOW
32.37
MARKET CAP
2.87B
P/E (TTM)
-5.9302
1D
5D
1M
3M
1Y
5Y
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
NASDAQ · 1d ago
Friday's ETF Movers: URA, ARKG
NASDAQ · 2d ago
Weekly Report: what happened at NTLA last week (0911-0915)?
Weekly Report · 6d ago
Intellia Therapeutics Enters Oversold Territory (NTLA)
NASDAQ · 09/13 20:19
Weekly Report: what happened at NTLA last week (0904-0908)?
Weekly Report · 09/11 12:26
‘Market May Be Broadening Out’: Cathie Wood Loads Up on These 2 Innovation Stocks
TipRanks · 09/05 13:52
Weekly Report: what happened at NTLA last week (0828-0901)?
Weekly Report · 09/05 11:37
Cathie Wood's Ark Invest Increases Palantir Exposure By $10.08M Amid Market Volatility, Offloads Shopify Stock
Benzinga · 09/01 02:47
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.